Indication
Biliary Tract Cancer
24 clinical trials
31 products
13 drugs
Product
CTX-009Clinical trial
A Phase 1b/2a Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-11-22
Product
IrinotecanProduct
PaclitaxelProduct
Telotristat ethylClinical trial
A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)Status: Terminated, Estimated PCD: 2022-01-13
Product
IBI310Product
sintilimabClinical trial
A Single Arm,Multi-center,Phase Ib/II Clinical Study Evaluating IBI310 Combined With Sintilimab in Patients With Advanced Biliary Tract Cance(BTC)Status: Recruiting, Estimated PCD: 2023-12-31
Product
GQ1001Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-11-28
Product
OxaliplatinProduct
5-FluorouracilProduct
INCB001158Product
LeucovorinProduct
GemcitabineProduct
CisplatinClinical trial
A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2024-05-30
Drug
FOLFOXIRIDrug
5-FUClinical trial
The Registry of Genetic Alterations of Taiwan Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2030-12-01
Product
Next-Generation SequencingClinical trial
A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare CancersStatus: Active (not recruiting), Estimated PCD: 2026-03-01
Product
IpilimumabProduct
NivolumabClinical trial
Phase I/II Clinical Trial of Regorafenib Plus Durvalumab (MEDI4736) in Patients With Chemo Refractory Advanced Biliary Tract CancersStatus: Recruiting, Estimated PCD: 2025-11-01
Product
DurvalumabDrug
RegorafenibClinical trial
Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based TreatmentStatus: Recruiting, Estimated PCD: 2026-06-30
Product
LenvatinibClinical trial
A Phase II Study of Immunotherapy With Durvalumab and Tremelimumab in Combination With Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
AN0025Product
TremelimumabDrug
UTD1Clinical trial
Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer: A Single Center, Single Arm, Phase II TrialStatus: Recruiting, Estimated PCD: 2024-09-01
Product
Cadonilimab+Regorafenib+GCClinical trial
The Efficacy and Safety of Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2023-10-10
Clinical trial
A Multicenter, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positive/Mutated Biliary Tract OR Colorectal Cancer.Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
SPH5030Clinical trial
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Who Have Failed to At Least 1 Prior Systemic TreatmentStatus: Active (not recruiting), Estimated PCD: 2023-07-31
Drug
SitravatinibProduct
TislelizumabClinical trial
A Phase II Study of Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Drug
H101Clinical trial
The Efficacy and Safety of KN026 Combination Chemotherapy ± KN046 in HER2-Positive Advanced Colorectal Cancer and Biliary Tract Cancer as First-Line Treatment： a Phase Ⅱ StudyStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Product
KN026Product
KN046Drug
XELOXClinical trial
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker StudyStatus: Recruiting, Estimated PCD: 2024-07-01
Product
Toripalimab + LenvatinibClinical trial
Hepatic Arterial Infusion Chemotherapy With Oxaliplatin, 5-fluorouracil and Bevacizumab Plus Intravenous Toripalimab for Advanced Biliary Tract CancerStatus: Completed, Estimated PCD: 2023-05-19
Clinical trial
A Phase II Study of Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Drug
PD-1 antibodyClinical trial
Camrelizumab Combined With Apatinib and Gemcitabine Plus Cisplatin as First-line Therapy for Patients With Inoperable/Metastatic Biliary Tract Cancer (BTC): An Open-label, Single-arm, Single-center, Phase Ib/II Clinical StudyStatus: Not yet recruiting, Estimated PCD: 2023-12-30
Clinical trial
Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid CancersStatus: Recruiting, Estimated PCD: 2028-01-04
Drug
DevimistatDrug
GemcitabineProduct
HydroxychloroquineClinical trial
A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
TS-1Drug
T-VEC